Table 4.
Risk of NHL in relation to variants in DNA repair genes, by NHL case pathology
|
AII B-cell
|
Follicular
|
DLBCL
|
AII T-cell
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA repair genes and variants | Cases | OR (95% CI) | P trend | Cases | OR (95% CI) | P trend | Cases | OR (95% CI) | P trend | Cases | OR (95% CI) | P trend | Controls |
| Nonhomologous end joining/V(D)J genes | |||||||||||||
| LIG4 (T9I) | |||||||||||||
| CC | 720 | 1.0 | 197 | 1.0 | 249 | 1.0 | 44 | 1.0 | 628 | ||||
| CT | 267 | 0.8 (0.7-1.0) | 68 | 0.8 (0.6-1.1) | 89 | 0.8 (0.6-1.1) | 24 | 1.2 (0.7-2.0) | 275 | ||||
| TT | 17 | 0.5 (0.3-1.0) | .02 | 2 | NC | — | 6 | 0.6 (0.2-1.4) | .07 | 1 | NC | — | 28 |
| CT or TT | 284 | 0.8 (0.7-1.0) | 70 | 0.7 (0.5-1.0) | 95 | 0.8 (0.6-1.0) | 25 | 1.2 (0.7-2.1) | 303 | ||||
| RAG1 (K820R) | |||||||||||||
| AA | 737 | 1.0 | 190 | 1.0 | 263 | 1.0 | 52 | 1.0 | 722 | ||||
| AG | 230 | 1.3 (1.0-1.6) | 59 | 1.3 (0.9-1.8) | 75 | 1.1 (0.8-1.6) | 16 | 1.2 (0.7-2.2) | 185 | ||||
| GG | 32 | 2.8 (1.5-5.3) | < .001 | 12 | 5.1 (2.3-11.7) | < .001 | 5 | 1.3 (0.2-9.8) | — | 1 | NC | — | 15 |
| AG or GG | 262 | 1.4 (1.1-1.7) | 71 | 1.5 (1.1-2.1) | 80 | 1.2 (0.7-2.2) | 17 | 1.2 (0.7-2.2) | 200 | ||||
| Homologous recombination (HR) repair | |||||||||||||
| BRCA2 (N372H) | |||||||||||||
| AA | 527 | 1.0 | 131 | 1.0 | 182 | 1.0 | 27 | 1.0 | 505 | ||||
| AC | 391 | 1.0 (0.8-1.2) | 110 | 1.1 (0.8-1.5) | 133 | 1.0 (0.8-1.3) | 35 | 1.8 (1.1-3.1) | 361 | ||||
| CC | 89 | 1.4 (1.0-2.1) | — | 25 | 1.6 (1.0-2.6) | — | 32 | 1.5 (1.0-2.4) | — | 9 | 3.0 (1.3-6.8) | .003 | 60 |
| CC or AC | 480 | 1.1 (0.9-1.3) | 135 | 1.2 (0.9-1.6) | 165 | 1.1 (0.8-1.4) | 44 | 2.0 (1.2-3.3) | 421 | ||||
| WRN (V114I) | |||||||||||||
| GG | 591 | 1.0 | 164 | 1.0 | 184 | 1.0 | 44 | 1.0 | 553 | ||||
| GA | 78 | 0.8 (0.6-1.1) | 22 | 0.8 (0.5-1.4) | 23 | 0.7 (0.5-1.2) | 6 | 0.8 (0.3-2.0) | 91 | ||||
| AA | 5 | 0.5 (0.2-1.5) | — | 1 | NC | — | 2 | NC | — | 0 | NC | — | 9 |
| GA or AA | 83 | 0.8 (0.6-1.0) | 23 | 0.7 (0.5-1.2) | 25 | 0.7 (0.3-1.8) | 6 | 0.7 (0.3-1.9) | 100 | ||||
| XRCC1 (R194W) | |||||||||||||
| CC | 828 | 1.0 | 218 | 1.0 | 289 | 1.0 | 57 | 1.0 | 804 | ||||
| CT | 167 | 1.4 (1.1-1.9) | .007 | 41 | 1.3 (0.9-2.0) | 52 | 1.3 (0.9-1.8) | 13 | 1.6 (0.8-3.0) | 116 | |||
| TT | 9 | 1.4 (0.5-3.9) | 4 | NC | — | 4 | NC | — | 0 | NC | — | 7 | |
| CT or TT | 176 | 1.4 (1.1-1.8) | 45 | 1.4 (1.0-2.1) | 56 | 1.3 (0.9-1.8) | 13 | 1.5 (0.8-2.8) | 123 | ||||
All analyses were adjusted for reference age (younger than 55 years, 55 to 64 years, 65 years or older), sex, race (White, African American, other), and study site. Participants with missing data are omitted. ICD-O codes for tumors included in each subgroup include the following: B-cell lymphoma: 9590, 9591, 9595, 9670-9673, 9675, 9676, 9678-9682, 9684, 9686-9688, 9690, 9691, 9695-9698, 9710, 9711, 9713, 9714; follicular lymphoma: 9676, 9690, 9691, 9695-9698; DLBCL: 9678-9682, 9684, 9688; T-cell lymphoma: 9700, 9702, 9705, 9706, 9708, 9709, 9713, 9714.
DLBCL indicates diffuse large B-cell lymphoma; OR, odds ratio; CI, confidence interval; NC, not calculated for cell sizes of 5 or fewer participants; and —, P > .05.